KRAS and carcinoma: We also included metastatic colorectal adenocarcinoma samples from the POG trial (n = 63) as an additional comparator, as colorectal adenocarcinoma represented an additional KRAS mutation-containing carcinoma cohort that were frequently biopsied from liver metastases (75% of samples biopsied from the liver, compared to 79% of cholangiocarcinoma and 86% of mPDAC samples).